ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Philadelphia, PA, USA:

Locations recently updated

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Camden, New Jersey, United States and 43 other locations

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC)....

Active, not recruiting
Metastatic Nonsquamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer
Drug: nab-Paclitaxel
Drug: Paclitaxel

Phase 3

Incyte
Incyte

Reading, Pennsylvania, United States and 140 other locations

Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal ant...

Active, not recruiting
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Other: Laboratory Biomarker Analysis
Drug: Carboplatin

Phase 1

Rutgers The State University of New Jersey
Rutgers The State University of New Jersey

Philadelphia, Pennsylvania, United States and 2 other locations

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The ...

Enrolling
Non-small Cell Lung Cancer
Drug: Pembrolizumab (MK-3475) 200 mg
Device: NovoTTF-200T

Phase 2

NovoCure
NovoCure

Wynnewood, Pennsylvania, United States and 23 other locations

HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

and osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Osimertinib
Drug: HER3-DXd

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Philadelphia, Pennsylvania, United States and 30 other locations

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Pennington, New Jersey, United States and 252 other locations

Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS)

combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small c ...

Active, not recruiting
Non-Small-Cell Lung Cancer
Drug: Amivantamab
Drug: Carboplatin

Phase 1

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Philadelphia, Pennsylvania, United States and 72 other locations

A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung ...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Pemetrexed/Carboplatin
Drug: Pemetrexed/Cisplatin

Phase 3

AstraZeneca
AstraZeneca

Philadelphia, Pennsylvania, United States and 152 other locations

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

in participants with Programmed death ligand-1 (PD L-1) high (Tumor cells \[TC\]/ Tumor proportion score \[TPS\] ≥ 50%), previously untreate...

Enrolling
Lung Cancer, Non-Small Cell
Drug: Belrestotug
Drug: GSK6097608

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Wynnewood, Pennsylvania, United States and 120 other locations

REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer (NSCLC).The prim...

Active, not recruiting
NSCLC
Drug: REGN5093

Phase 1, Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Philadelphia, Pennsylvania, United States and 29 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems